LON:VSN

Verseon Share Forecast, Price & News

GBX 74
+1.50 (+2.07 %)
(As of 03/15/2019)
Add
Compare
Today's Range
74
Now: GBX 74
74
50-Day Range
74
MA: GBX 74
74
52-Week Range
72.50
Now: GBX 74
146.50
Volume3,000 shs
Average Volume75,334 shs
Market Capitalization£112.24 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Verseon Corporation, a pharmaceutical company, designs and develops novel therapeutics for various diseases in the United States. The company is involved in developing oral anticoagulants for various cardiovascular indications with novel pharmacology; kallikrein inhibitors for the treatment of diabetic macular edema and hereditary angioedema; and novel angiogenesis inhibitors for the treatment of solid tumors. Verseon Corporation was founded in 2002 and is headquartered in Fremont, California.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-510-2259000
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash FlowGBX 11.19 per share
Book ValueGBX 21 per share

Profitability

Miscellaneous

Market Cap£112.24 million
Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

0.48 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
GBX 74
+1.50 (+2.07 %)
(As of 03/15/2019)
30 days | 90 days | 365 days | Advanced Chart

Receive VSN News and Ratings via Email

Sign-up to receive the latest news and ratings for VSN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Verseon (LON:VSN) Frequently Asked Questions

What stocks does MarketBeat like better than Verseon?

Wall Street analysts have given Verseon a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Verseon wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are Verseon's key executives?

Verseon's management team includes the following people:
  • Mr. Adityo Prakash, CEO & Exec. Director
  • Ms. Eniko Fodor, Founder, CFO, COO, Company Sec. & Exec. Director (Age 51)

Who are some of Verseon's key competitors?

What is Verseon's stock symbol?

Verseon trades on the London Stock Exchange (LON) under the ticker symbol "VSN."

How do I buy shares of Verseon?

Shares of VSN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Verseon's stock price today?

One share of VSN stock can currently be purchased for approximately GBX 74.

How much money does Verseon make?

Verseon has a market capitalization of £112.24 million.

What is Verseon's official website?

The official website for Verseon is www.verseon.com.

Where are Verseon's headquarters?

Verseon is headquartered at 48820 Kato Rd Ste 100B, FREMONT, CA 94538-7323, United States.

How can I contact Verseon?

Verseon's mailing address is 48820 Kato Rd Ste 100B, FREMONT, CA 94538-7323, United States. The company can be reached via phone at +1-510-2259000.


This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.